Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › XENE

DRIEHAUS CAPITAL MANAGEMENT LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 4,418,557 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$266.7M, representing 1.55% of its reported portfolio and ranking #4 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)4.42M sh
Reported value held$266.70M
Portfolio Weight1.55%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DRIEHAUS CAPITAL MANAGEMENT LLC's XENE position evolved

DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in XENE in Q3 2023 at 4,513,005 shares (US$154.2M). The position peaked in Q2 2026 at 4,418,557 shares, worth US$266.7M. Across 12 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,418,557 shares valued at US$266.7M — a reduction of -73,096 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.51M $154.16M New
Q4 2023 4.35M $200.14M Reduce
Q1 2024 4.32M $186.05M Reduce
Q2 2024 4.42M $172.32M Add
Q3 2024 4.60M $180.93M Add
Q4 2024 4.52M $177.21M Reduce
Q1 2025 4.58M $153.82M Add
Q2 2025 4.34M $135.71M Reduce
Q3 2025 4.17M $167.39M Reduce
Q4 2025 4.54M $203.42M Add
Q1 2026 4.49M $261.19M Reduce
Q2 2026 4.42M $266.70M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has DRIEHAUS CAPITAL MANAGEMENT LLC held XENE?

DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in XENE?

As of Q2 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 4.42M shares of XENE (XENON PHARMACEUTICALS INC), valued at $266.70M, representing 1.55% of its reported portfolio and ranking #4.

Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), DRIEHAUS CAPITAL MANAGEMENT LLC reduced its position in XENE. The position peaked in Q2 2026 at 4.42M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DEERFIELD MANAGEMENT COMPANY, L.P., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.